Results 111 to 120 of about 365,877 (337)

Deep Learning‐Powered Scalable Cancer Organ Chip for Cancer Precision Medicine

Advanced Science, EarlyView.
This scalable, low‐cost Organ Chip platform, made via injection molding, uses capillary pinning for hydrogel confinement and supports versatile tissue coculture and robust imaging. Deep learning enables label‐free, sensitive phenotypic analysis.
Yu‐Chieh Yuan, Beibei Xu, Jenna McCormack, XuHai Huang, Jingzhe Ma, Thomas Marshall, Yacong Sun, Hardeep Singh, Alyssa Fanelli, Gauri Kulkarni, Ji Hye Seo, Paige Gilbride, Bing Wei, Bo Wang, Yanyan Liu, Fei Ma, Lin Zhou, Shuyang Wang, Xiaohua Qian, Zhiyong Xie, Polina Golland, Longlong Si, Yu Shrike Zhang, Xin Xie, Haiqing Bai   +24 more
wiley   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Phase i study of \u27dose-dense\u27 pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma. [PDF]

, 2011
BACKGROUND: This phase I study investigates the feasibility of carboplatin plus dose-dense (q2-week) pemetrexed given concurrently with radiotherapy (XRT) for locally advanced and oligometastatic non-small cell lung cancer (NSCLC).
Axelrod, Rita, Curran, Walter J, Denittis, Albert, Gilman, Paul, Machtay, Mitchell, Meyer, Thomas, Shen, Xinglei, Treat, Joseph, Werner-Wasik, Maria   +8 more
core   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

The impact of artificial intelligence on a multi-omics approach toward predictive biomarkers for non-small cell lung cancer [PDF]

Exploration of Digital Health Technologies
Over the last four decades, lung cancer has been the leading cause of death in the United States. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and historically, treatment consists of surgical resection, chemotherapy, and/or ...
Brandon Wilkins, Emily Hartman, Blake Kelley, Pranali Pachika, Joshua Bradley, James Bradley   +5 more
doaj   +1 more source

Review for "NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment"

, 2021

openalex   +1 more source

Quantification of [18F]afatinib using PET/CT in NSCLC patients, a feasibility study [PDF]

, 2020
Eveline Annette van de Stadt, Maqsood Yaqub, Adriaan A. Lammertsma, Alex J. Poot, Patrick Schober, Robert C. Schuit, Egbert F. Smit, Idris Bahce, Harry Hendrikse   +8 more
openalex   +1 more source

Pro‐ATO/Allicin Liposomes for Dual‐Pathway Targeting of p53‐Mutant Tumors

Advanced Science, EarlyView.
Schematic illustration of the “pro‐ATO”/allicin liposomal strategy. Liposomal encapsulation improves the stability and bioavailability of both agents while masking allicin's odor. Upon release in the tumor microenvironment, ATO reactivates structural p53 mutants, and allicin inhibits ATR signaling while releasing H2S, collectively inducing synthetic ...
Xiaoling Xu, WeiYi Cheng, Menghang Yang, Li He, WeiYe Ren, JingQuan Chen, LiTing He, Dandan Bao, Zhihong Zhu, Lixin Wang, Qinghua Yao, Ji‐Gang Piao   +11 more
wiley   +1 more source

Supplementary Table S1 from Phase II Study of Docetaxel and Trametinib in Patients with <i>KRAS</i> Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

, 2023
Shirish M. Gadgeel, Jieling Miao, Jonathan W. Riess, James Moon, Philip C. Mack, Gregory J. Gerstner, Timothy F. Burns, Asma Taj, Wallace Akerley, Konstantin H. Dragnev, Noel Laudi, Mary W. Redman, Jhanelle E. Gray, David R. Gandara, Karen Kelly   +14 more
openalex   +1 more source

Decoding the Cardiac Immune Microenvironment and Fibroblast Crosstalk in Radiotherapy Combined with Immunotherapy‐Induced Cardiac Fibrosis Based on Single‐Cell Transcriptomic Analysis

Advanced Science, EarlyView.
This study highlights that radioimmunotherapy drives crosstalk between fibroblasts and immune cells (especially macrophages) in the cardiac microenvironment, with IL‐6 as the key mediator, and tocilizumab alleviates cardiac fibrosis by targeting this interplay.
Yuxi Luo, Ying Yu, Zhimin Zeng, Yanxin Chen, Yali Yi, Zhiqin Lu, Fujuan Zeng, Peng Xu, Daya Luo, Leifeng Chen, Anwen Liu   +10 more
wiley   +1 more source